Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23626889 | 0.98 | TSHR (0.35) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23626836 | 0.96 | ALDH1A1 (0.33) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23626832 | 0.96 | ALOX5 (0.35) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23626837 | 0.96 | ALDH1A1 (0.34) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23626827 | 0.95 | PRKDC (0.36) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23626884 | 0.95 | PRKDC (0.36) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23626825 | 0.94 | ALDH1A1 (0.34) | ALDH1A1TSHRCYP2C19ALOX5PIK3CA | |
| SCHEMBL23626821 | 0.94 | ALOX5 (0.35) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23627201 | 0.94 | ALOX5 (0.35) | ALDH1A1TSHRCYP2C19ALOX5PRKDC | |
| SCHEMBL23626881 | 0.94 | ALDH1A1 (0.32) | ALDH1A1TSHRCYP2C19ALOX5PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873311-B2 | Heterocyclic compound, organic electroluminescent device, and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11873311-B2 | Heterocyclic compound, organic electroluminescent device, and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230312604-A1 | HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312604-A1 | HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2021136277-A1 | HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC DEVICE | 陕西莱特光电材料股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312604-A1 | HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC DEVICE | ODC1, LEF1, PIEZO1 | ALDH1A1 137/4885TSHR 3792/4885CYP2C19 29/4885 |
| US-11873311-B2 | Heterocyclic compound, organic electroluminescent device, and electronic device | ODC1, LEF1, PIEZO1 | ALDH1A1 137/4885TSHR 3792/4885CYP2C19 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.